H.C. Wainwright maintains AnaptysBio stock Neutral rating, $19 target
AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...
Vanda stock holds Buy rating, $18 target from H.C. Wainwright
H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...
What is HC Wainwright’s Forecast for BTAI FY2024 Earnings?
Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...
HC Wainwright Has Pessimistic Outlook of SLN FY2024 Earnings
Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Silence Therapeutics in a report issued on ...
BlackSky price target raised to $20 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BlackSky (BKSY) to $20 from $12 and keeps a Buy rating on the shares. The firm says that as ...
Xoma price target lowered to $104 from $123 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Xoma (XOMA) to $104 from $123 and keeps a Buy rating on the shares. The firm removed ...
Nasdaq1mon
MetaVia initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...
Nasdaq7d
HC Wainwright & Co. Initiates Coverage of Knightscope (KSCP) with Buy Recommendation
Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Knightscope (NasdaqCM:KSCP) with a Buy recommendation. As of January 28, 2025, the average one-year price target ...